Clinicopathologic study of E-cadherin/beta-catenin complex, and topoisomerase-II in a series of 71 liposarcoma cases

World Journal of Surgical Oncology

Periclis Tsekeris¹  Nikoforos Apostolikas³  Dimitrios Stefanou²  Evangelos Briasoulis¹  Ioannis Panelos²  Anna Batistatou²  Emilios Pakos⁴  Pinelopi Gogou⁴ 

[1] Cancer Biobank Center, University of Ioannina, University Campus P.O. Box 1186, 45110 Ioannina, Greece;Department of Pathology, University of Ioannina, Medical School, Ioannina, Greece, Stavrou Niarhou Av 1., 45500 Ioannina, Greece;Department of Pathology, St Savvas Cancer Hospital, Athens, Greece;Department of Radiation Oncology, University Ioannina, Medical School, Stavrou Niarhou Av 1., 45500 Ioannina, Greece

关键词: prognosis;    topoisomerase II alpha;    b-catenin;    E-cadherin;    liposarcomas;   

Others  :  828007
DOI  :  10.1186/1477-7819-10-28

 received in 2011-05-10, accepted in 2012-02-02,  发布年份 2012

【 摘 要 】

Background

To investigate the expression of E-cadherin, beta-catenin and topoisomerase-II alpha and examine their clinical relevance in liposarcomas.

Materials and methods

The expression of E-cadherin, beta-catenin and topoisomerase II alpha was examined immunohistochemically on formalin-fixed paraffin-embedded tissue specimens from 71 patients who underwent surgical treatment for liposarcomas of the extremities or the retroperitoneum in two major cancer reference centres between 1990 and 2000. Detailed medical notes were available for all patients who were followed for median 82 months (range 5 to 215 months). Obtained expression data were weighted against clinical and pathology parameters of clinical relevance.

Results

Patients were mostly male (59%), median age was 56 years for the liposarcomas of the extremities and 60 years for the retroperitoneal liposarcomas. The tumours were of diverse histology, grade and size (median diameters 7 and 17 cm for tumours of the extremities and retroperitoneum respectively). Expression of β-catenin protein was weakly detected in 15 cases (21.1%). Similarly weak expression of topoisomerase II-alpha was detected in 14 (19.7%) cases of which only two had more than 20% of tumor cells stained positive. E-cadherin was not detected in the studied cohort of liposarcomas. We did not detect associations between the expression of the above proteins by liposarcoma cells and clinical outcome.

Conclusions

Liposarcomas do not express E-cadherin, which matches the absence of epithelioid differentiation in this sarcoma subtype, and have low topoisomerase II-alpha expression, which justifies to some extend their resistance to anthracycline-based chemotherapy.

【 授权许可】

   
2012 Gogou et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Coindre JM, Pedeutour F, Aurias A: Well-differentiated and dedifferentiated liposarcomas. Virchows Arch 2010, 456(2):167-179.
• [2]Clark MA, Fisher C, Judson I, Thomas JM: Soft-tissue sarcomas in adults. N Engl J Med 2005, 353(7):701-711.
• [3]Fletcher CD: The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology 2006, 48(1):3-12.
• [4]Reitan JB, Kaalhus O: Radiotherapy of liposarcomas. Br J Radiol 1980, 53(634):969-975.
• [5]Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, Judson I: Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer 2008, 112(7):1585-1591.
• [6]Fritz B, Schubert F, Wrobel G, Schwaenen C, Wessendorf S, Nessling M, Korz C, Rieker RJ, Montgomery K, Kucherlapati R, et al.: Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma. Cancer Res 2002, 62(11):2993-2998.
• [7]Sato H, Hasegawa T, Abe Y, Sakai H, Hirohashi S: Expression of E-cadherin in bone and soft tissue sarcomas: a possible role in epithelial differentiation. Hum Pathol 1999, 30(11):1344-1349.
• [8]Moon RT: Wnt/beta-catenin pathway. Sci STKE 2005, 2005(271):cm1.
• [9]Nelson WJ, Nusse R: Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004, 303(5663):1483-1487.
• [10]Jeanes A, Gottardi CJ, Yap AS: Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 2008, 27(55):6920-6929.
• [11]Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K: Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res 2000, 6(12):4789-4796.
• [12]Nitiss JL: DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer 2009, 9(5):327-337.
• [13]Esteva FJ, Hortobagyi GN: Topoisomerase II{alpha} amplification and anthracycline-based chemotherapy: the jury is still out. J Clin Oncol 2009, 27(21):3416-3417.
• [14]Nitiss JL: Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009, 9(5):338-350.
• [15]Gogou PN, Batistatou A, Pakos EE, Apostolikas N, Stefanou D, Tsekeris PG: E-cadherin, b-catenin and topoisomerase II expression in rhabdomyosarcomas. J BUON 2009, 14(2):323-324.
• [16]Yoo J, Park S, Kang CS, Kang SJ, Kim BK: Expression of E-cadherin and p53 proteins in human soft tissue sarcomas. Arch Pathol Lab Med 2002, 126(1):33-38.
• [17]Ng TL, Gown AM, Barry TS, Cheang MC, Chan AK, Turbin DA, Hsu FD, West RB, Nielsen TO: Nuclear beta-catenin in mesenchymal tumors. Mod Pathol 2005, 18(1):68-74.
• [18]Sakamoto A, Oda Y, Adachi T, Saito T, Tamiya S, Iwamoto Y, Tsuneyoshi M: Beta-catenin accumulation and gene mutation in exon 3 in dedifferentiated liposarcoma and malignant fibrous histiocytoma. Arch Pathol Lab Med 2002, 126(9):1071-1078.
• [19]Clevers H: Wnt/beta-catenin signaling in development and disease. Cell 2006, 127(3):469-480.
• [20]Hasegawa T, Yokoyama R, Matsuno Y, Shimoda T, Hirohashi S: Prognostic significance of histologic grade and nuclear expression of beta-catenin in synovial sarcoma. Hum Pathol 2001, 32(3):257-263.
• [21]Abeler VM, Royne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB: Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 2009, 54(3):355-364.
• [22]Hsu PK, Li AF, Wang YC, Hsieh CC, Huang MH, Hsu WH, Hsu HS: Reduced membranous beta-catenin protein expression is associated with metastasis and poor prognosis in squamous cell carcinoma of the esophagus. J Thorac Cardiovasc Surg 2008, 135(5):1029-1035.
• [23]Rosen DG, Zhang Z, Chang B, Wang X, Lin E, Liu J: Low membranous expression of beta-catenin and high mitotic count predict poor prognosis in endometrioid carcinoma of the ovary. Mod Pathol 2010, 23(1):113-122.
• [24]Gogou PN, Batistatou A, Pakos EE, Apostolikas N, Stefanou D, Tsekeris PG: Expression of E-cadherin, beta-catenin and topoisomerase IIalpha in leiomyosarcomas. Clin Transl Oncol 2009, 11(8):548-551.
• [25]Chikamori K, Grozav AG, Kozuki T, Grabowski D, Ganapathi R, Ganapathi MK: DNA Topoisomerase II Enzymes as Molecular Targets for Cancer Chemotherapy. Curr Cancer Drug Targets 2010.
• [26]Rody A, Karn T, Ruckhaberle E, Muller V, Gehrmann M, Solbach C, Ahr A, Gatje R, Holtrich U, Kaufmann M: Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer. Breast Cancer Res Treat 2009, 113(3):457-466.
• [27]Endo H, Hirokawa M, Ishimaru N, Tanaka Y, Yamashita M, Sakaki M, Hayashi Y, Sano T: Unique cell membrane expression of topoisomerase-II alpha as a useful diagnostic marker of liposarcoma. Pathol Int 2004, 54(3):145-150.
• [28]Krikelis D, Judson I: Role of chemotherapy in the management of soft tissue sarcomas. Expert Rev Anticancer Ther 2010, 10(2):249-260.